A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease.

Trial Profile

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE-PD
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 09 Feb 2018 Results of post hoc analysis assessing the effect of concomitant medications on safety and efficacy of extended release Carbidopa-Levodopa using patient data from ADVANCE-PD and ASCEND-PD trials published in the Clinical Neuropharmacology
    • 28 Apr 2017 Results of a post-hoc subgroup analysis evaluating the efficacy of extended-release carbidopa-levodopa in advanced Parkinson's disease patients with or without concomitant medication use, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of a post-hoc analysis assessing the effect of "OFF" time on the recommended starting dose of extended-release carbidopa-levodopa capsules, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top